cc-90011
Small moleculeexperimental
Clinical trial activity
5 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2016 (NCT02875223)
Timeline
Indications
Mechanism of action
- LSD1/CoREST complexINHIBITOR
LSD1/CoREST complex inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cc-90011
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04748848 | Phase 1/Phase 2 (Phase 2) | Oct 14, 2021 | Bristol-Myers Squibb, Celgene |
| NCT04628988 | Phase 1 | Dec 17, 2020 | Celgene |
| NCT04350463 | Phase 2 | Apr 20, 2020 | Celgene |
| NCT03850067 | Phase 1/Phase 2 (Phase 2) | Mar 12, 2019 | Celgene, Institut Gustave Roussy, Marche Polytechnic University, University of Bologna, University of Valencia, Vita-Salute University of Milano. Italy |
| NCT02875223 | Phase 1 | Aug 1, 2016 | Celgene, Institut Gustave Roussy, Royal Marsden Hospital NHS Trust |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celgene | For profit | 5 | 5 | 2 | 2016 |
| Institut Gustave Roussy | Academic/Hospital | 2 | 0 | 2 | 2016 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2021 |
| Marche Polytechnic University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Royal Marsden Hospital NHS Trust | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Bologna | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Valencia | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Vita-Salute University of Milano. Italy | Academic/Hospital | 1 | 0 | 1 | 2019 |
8 organizations
Page 1 / 1